US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 10:16:55 Source:entertainmentViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Pogacar extends Giro lead to over 7 minutes after winning altered Stage 16 amid protests at start
Next:Kentucky congressman expects no voter fallout for his role in attempt to oust House speaker
You may also like
- Haiti’s international airport reopens after gang violence
- Hundreds of prisoners set to be freed early to ease pressure on crowded jails
- Mother's Day: Today, more US parents than ever have paid leave — but most still don't
- Profound sadness, anger grips Israel on Memorial Day
- Garcia, Winker go deep as Nats end slide, beat struggling Twins 12
- UK foreign secretary David Cameron says halting arms sales to Israel would strengthen Hamas
- Schools turn to artificial intelligence to spot guns as companies press for state funds
- DAN HODGES: Keir Starmer has sold his soul to hard
- Turkish Airlines resumes flights to Afghanistan nearly 3 years after the Taliban captured Kabul